位置:首页 > 产品库 > CPI-1205
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CPI-1205
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CPI-1205图片
CAS NO:1621862-70-1
规格:98%
分子量:518.57
包装与价格:
包装价格(元)
2mg询价
5mg询价
25mg询价

EZH2 inhibitor
CAS:1621862-70-1
分子式:C27H33F3N4O3
分子量:518.57
纯度:98%
存储:Store at -20°C

Background:

0.002 μM for biochemical IC50; 0.032 μM for cellular EC50.


CPI-1205 is an EZH2 inhibitor.


Polycomb repressive complex 2 (PRC2) plays a key role in transcriptional silencing partially by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function relates with certain malignancies and poor prognosis. EZH2 is thus representing a promising candidate oncology target for pharmacological intervention.


In vitro: Previous study reported that the treatment with CPI-1205 caused apoptosis in multiple myeloma and plasmacytoma cell models. CPI-1205 also had a clean selectivity profile when tested against 30 other histone or DNA methyltransferases. In addition, CPI-1205 demonstrated modest selectivity when tested against enhancer of zeste homologue 1 (EZH1) that is a methyltransferase highly related to EZH2 [1].


In vivo: In animal study, CPI-1205 was dosed at 160 mg/kg orally twice daily for 25 days in tumor bearing female CB-17 SCID mice. By the treatment of tumor-bearing mice with CPI-1205, tumor regression was observed within two weeks. By the end of day 25, significant tumor growth inhibition was recorded. CPI-1205 was found to be well-tolerated for repeat dosing as observed by the absence of significant body weight loss. In addition, analysis of plasma and tumor at 1 h post last dose on day 25 showed sufficient plasma and tumor tissue concentrations [1].


Clinical trial: A study to evaluate CPI-1205 in patients with B-cell lymphomas is currently recruiting participants [2].


参考文献:
[1] Vaswani RG et al.  Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas. J Med Chem. 2016 Nov 10;59(21):9928-9941.
[2] https://clinicaltrials. gov/ct2/show/NCT02395601 term=CPI-1205&rank=1.


 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024